% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Kuramatsu:255985,
author = {Kuramatsu, Joji B. and Gerner, Stefan T. and Schellinger,
Peter D. and Glahn, Jörg and Endres, Matthias and Sobesky,
Jan and Flechsenhar, Julia and Neugebauer, Hermann and
Jüttler, Eric and Grau, Armin and Palm, Frederick and
Röther, Joachim and Michels, Peter and Hamann, Gerhard F.
and Hüwel, Joachim and Hagemann, Georg and Barber, Beatrice
and Terborg, Christoph and Trostdorf, Frank and Bäzner,
Hansjörg and Roth, Aletta and Wöhrle, Johannes and Keller,
Moritz and Schwarz, Michael and Reimann, Gernot and
Volkmann, Jens and Müllges, Wolfgang and Kraft, Peter and
Classen, Joseph and Hobohm, Carsten and Horn, Markus and
Milewski, Angelika and Reichmann, Heinz and Schneider, Hauke
and Schimmel, Eik and Fink, Gereon R. and Dohmen, Christian
and Stetefeld, Henning and Witte, Otto and Günther,
Albrecht and Neumann-Haefelin, Tobias and Racs, Andras E.
and Nueckel, Martin and Erbguth, Frank and Kloska, Stephan
P. and Dörfler, Arnd and Köhrmann, Martin and Schwab,
Stefan and Huttner, Hagen B.},
title = {{A}nticoagulant {R}eversal, {B}lood {P}ressure {L}evels,
and {A}nticoagulant {R}esumption in {P}atients {W}ith
{A}nticoagulation-{R}elated {I}ntracerebral {H}emorrhage},
journal = {The journal of the American Medical Association},
volume = {313},
number = {8},
issn = {0098-7484},
address = {Chicago, Ill.},
publisher = {American Medical Association},
reportid = {FZJ-2015-06043},
pages = {824 - 836},
year = {2015},
abstract = {Importance Although use of oral anticoagulants (OACs) is
increasing, there is a substantial lack of data on how to
treat OAC-associated intracerebral hemorrhage
(ICH).Objective To assess the association of anticoagulation
reversal and blood pressure (BP) with hematoma enlargement
and the effects of OAC resumption.Design, Setting, and
Participants Retrospective cohort study at 19 German
tertiary care centers (2006-2012) including 1176 individuals
for analysis of long-term functional outcome, 853 for
analysis of hematoma enlargement, and 719 for analysis of
OAC resumption.Exposures Reversal of anticoagulation during
acute phase, systolic BP at 4 hours, and reinitiation of OAC
for long-term treatment.Main Outcomes and Measures Frequency
of hematoma enlargement in relation to international
normalized ratio (INR) and BP. Incidence analysis of
ischemic and hemorrhagic events with or without OAC
resumption. Factors associated with favorable (modified
Rankin Scale score, 0-3) vs unfavorable functional
outcome.Results Hemorrhage enlargement occurred in 307 of
853 patients $(36.0\%).$ Reduced rates of hematoma
enlargement were associated with reversal of INR levels <1.3
within 4 hours after admission (43/217 $[19.8\%])$ vs INR of
≥1.3 (264/636 $[41.5\%];$ P < .001) and systolic BP
<160 mm Hg at 4 hours (167/504 $[33.1\%])$ vs ≥160 mm Hg
(98/187 $[52.4\%];$ P < .001). The combination of INR
reversal <1.3 within 4 hours and systolic BP of <160 mm Hg
at 4 hours was associated with lower rates of hematoma
enlargement (35/193 $[18.1\%]$ vs 220/498 $[44.2\%]$ not
achieving these values; OR, 0.28; $95\%$ CI, 0.19-0.42;
P < .001) and lower rates of in-hospital mortality
(26/193 $[13.5\%]$ vs 103/498 $[20.7\%];$ OR, 0.60; $95\%$
CI, 0.37-0.95; P = .03). OAC was resumed in 172 of 719
survivors $(23.9\%).$ OAC resumption showed fewer ischemic
complications (OAC: 9/172 $[5.2\%]$ vs no OAC: 82/547
$[15.0\%];$ P < .001) and not significantly different
hemorrhagic complications (OAC: 14/172 $[8.1\%]$ vs no OAC:
36/547 $[6.6\%];$ P = .48). Propensity-matched survival
analysis in patients with atrial fibrillation who restarted
OAC showed a decreased HR of 0.258 $(95\%$ CI, 0.125-0.534;
P < .001) for long-term mortality. Functional long-term
outcome was unfavorable in 786 of 1083 patients
$(72.6\%).Conclusions$ and Relevance Among patients with
OAC-associated ICH, reversal of INR <1.3 within 4 hours and
systolic BP <160 mm Hg at 4 hours were associated with lower
rates of hematoma enlargement, and resumption of OAC therapy
was associated with lower risk of ischemic events. These
findings require replication and assessment in prospective
studies.},
cin = {INM-3},
ddc = {610},
cid = {I:(DE-Juel1)INM-3-20090406},
pnm = {572 - (Dys-)function and Plasticity (POF3-572)},
pid = {G:(DE-HGF)POF3-572},
typ = {PUB:(DE-HGF)16},
UT = {WOS:000349826400016},
pubmed = {pmid:25710659},
doi = {10.1001/jama.2015.0846},
url = {https://juser.fz-juelich.de/record/255985},
}